Phio intasyl
Phio's technology platform (INTASYL) allows the development of 'self-delivering’ RNAi compounds, or 'sd-rxRNA' for short, in which drug-like properties were built into the RNAi compound itself, rather than relying on liposomal delivery to improve circulation time and cellular uptake. This platform was developed through systematic medicinal chemistry screening and they have shown the utility of their platform in three papers. Webb7 maj 2024 · On May 4, 2024 PHIO will present new data showing INTASYL PH-762-treated of HER2CART cells (PH-762 HER2CART) exerted statistically significant, robust, and durable inhibition of tumor...
Phio intasyl
Did you know?
WebbINTASYL is Phio’s proprietary self-delivering RNAi technology, which is designed to make immune cells more effective in killing tumor cells. The posters will be presented by Ben … Webb10 apr. 2024 · Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system.
Webb4 apr. 2024 · MARLBOROUGH, Mass., Nov. 10, 2024 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended September … WebbPhio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform.
WebbPhio is maximizing the value of the self-delivering RNAi technology for I/O by Developing adoptive cell therapy (ACT) products with increased antitumor effectiveness in … Webb21 dec. 2024 · Phio is a clinical stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology is designed to make immune cells more effective in …
Webb16 sep. 2024 · MARLBOROUGH, Mass., Sept. 16, 2024 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO ), a biotechnology company developing the next generation of immuno-oncology therapeutics based on...
Webb22 feb. 2024 · Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its … rcpch annual accountsWebb11 maj 2024 · Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. rcpch advanced practiceWebb19 apr. 2016 · Phio Pharmaceuticals Corp. is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL... rcpch application st1WebbPhio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering … rcpch annual conference abstractWebb11 mars 2024 · MARLBOROUGH, Mass., March 11, 2024 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next … rcpch advice sheetWebb13 mars 2024 · MARLBOROUGH, Mass., Feb. 10, 2024 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that an independent Data Monitoring … rcpch annual meetingWebb16 sep. 2024 · Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self … sims ears